Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Last trade$19.28
Day change+$0.17 (+0.89%)
Day range$18.82 – $19.44
Volume100,948
Market cap$657M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$657.17M
Price / earnings
—
Price / book
5.19×
Price / sales
—
EV / sales
—
EV / EBITDA
-9.91×
Profitability
Earnings per share
-$1.47
Return on assets
-35.82%
Return on equity
-39.84%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.92×
Quick ratio
9.92×
Cash ratio
9.91×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.29M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NVCT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.68M
$2.51M
$2.15M
$2.53M
$2.02M
$2.98M
$1.89M
$1.95M
Research and development
$27.37M
$4.68M
$4.11M
$5.09M
$5.77M
$3.61M
$3.68M
$4.5M
Total operating expenses
$31.05M
$7.2M
$6.26M
$7.62M
$7.79M
$6.6M
$5.57M
$6.45M
Operating income
-$31.05M
-$7.2M
-$6.26M
-$7.62M
-$7.79M
-$6.6M
-$5.57M
-$6.45M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$30.07M
-$7.02M
-$6.05M
-$7.31M
-$7.46M
-$6.33M
-$5.33M
-$6.25M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$30.07M
-$7.02M
-$6.05M
-$7.31M
-$7.46M
-$6.33M
-$5.33M
-$6.25M
Net income attributable to common shareholders
-$30.07M
-$7.02M
-$6.05M
-$7.31M
-$9.89M
-$6.33M
-$5.33M
-$6.25M
EBITDA
-$31.05M
-$7.2M
-$6.26M
-$7.62M
-$7.79M
-$6.6M
-$5.57M
-$6.45M
Basic earnings per share
-$1.02
-$0.30
-$0.26
-$0.31
-$0.44
-$0.30
-$0.27
-$0.35
Diluted earnings per share
-$1.02
-$0.30
-$0.26
-$0.31
-$0.44
-$0.30
-$0.27
-$0.35
Recent news
Company coverage with links to the original publishers.
Nuvectis Pharma announced it will host a conference call on November 4, 2026 at 8:00 AM ET to discuss Q3 2026 business progress and financial results. The clinical-stage biopharmaceutical company is focused on developing therapies for complement-related conditions and oncology, with lead candidate NXP100 (ciprocopan) recently approved in China for PNH treatment.
Nuvectis Pharma (Nasdaq: NVCT), a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 5 million shares at $20.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to advance development of its pipeline candidates NXP100, NXP200, and NXP900, hire personnel, and cover operational expenses. The offering is expected to close on July 1, 2026.
Nuvectis Pharma announced three poster presentations for its clinical-stage drug NXP900, a first-in-class YES1/SRC inhibitor, at the 2026 AACR Meeting in San Diego (April 17-22). The presentations will showcase NXP900's synergy with KRAS inhibitors in NSCLC models, strategies to overcome drug resistance in cholangiocarcinoma, and its potential to restore antitumor immunity by targeting myeloid-derived suppressor cells.
Nuvectis Pharma, a clinical-stage biopharmaceutical company, announced the pricing of its $13.5 million public offering of 2.7 million shares of common stock at $5 per share. The company plans to use the proceeds to advance the development of its drug candidates NXP800 and NXP900.
Nuvectis Pharma, Inc. reported its Q3 2024 financial results and provided updates on the development of its drug candidates NXP800 and NXP900. The company expects a clinical data update for NXP800 this month and has progressed the NXP900 Phase 1a study with no dose-limiting toxicities.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.